Therapies for autoimmune diseases are available but do not work for all patients, and when they do, side effects can be severe. There is a strong need for new therapies and therefore there is a large market potential, especially for treatments targeting rheumatoid arthritis and multiple sclerosis. In this third segment of the article series, BioStock takes a look at some Swedish companies that aim to take position in these markets by developing new drugs for RA and MS.

"Interestingly, we have also seen positive results in models where anti-TNF antibodies do not work. This indicates that we provide a new and unique mode of action", says Einar Pontén, CEO.

Read the article from Biostock here ►